Brief: Clene Reports Reduction in Biomarker Plasma Neurofilament Light Levels and Improved Survival With CNM-Au8 Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Clene

21/12/2023 12:24

Dec 21 (Reuters) - Clene Inc.  CLNN.O :
    * CLENE REPORTS REDUCTION IN BIOMARKER PLASMA NEUROFILAMENT
LIGHT
(NFL) LEVELS AND IMPROVED SURVIVAL WITH CNM-AU8® TREATMENT FROM
HEALEY ALS PLATFORM TRIAL LONG-TERM OPEN LABEL EXTENSION
    * CLENE INC.: CNM-AU8 30MG TREATMENT DEMONSTRATED
SIGNIFICANTLY
REDUCED PLASMA NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS AT 76
WEEKS RELATIVE TO PLACEBO
    * CLENE : CNM-AU8 30MG HAD GREATER OVERALL TREATMENT EFFECT
IN
DELAYING TIME TO MORBIDITY EVENTS IN HIGHEST RISK PARTICIPANTS
BASED ON BASELINE NFL LEVELS

Source text for Eikon:  ID:nGNX6y8QK7 
Further company coverage:  CLNN.O 

 ((Reuters.Briefs@thomsonreuters.com;))